ADHD drug trial offers hope for debilitating cancer survivor fatigue
NCT ID NCT06905587
Summary
This study is testing whether methylphenidate, a medication commonly used for ADHD, can help reduce severe, long-lasting fatigue in people who survived a childhood brain tumor. Fifty eligible survivors will try both the drug and a placebo in a random order to see which one better improves their energy and thinking skills. The goal is to find an evidence-based treatment for this common and debilitating side effect of cancer therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN TUMOR, PEDIATRIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aalborg University Hospital
NOT_YET_RECRUITINGAalborg, 9000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Aarhus University Hospital
NOT_YET_RECRUITINGAarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Odense University Hospital
RECRUITINGOdense, 5000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Rigshospitalet
NOT_YET_RECRUITINGCopenhagen, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.